Firazorexton

DB19440InvestigationalSmall molecule

Firazorexton is under investigation in clinical trial NCT04096560 (A Study of TAK-994 in Adults With Type 1 and Type 2 Narcolepsy).

Mechanism: Pharmacologically active on Orexin receptor type 2
Curator reviewed
Formula / weight: C₂₂H₂₅F₃N₂O₄S · 470.51 g/mol (avg)
Also known as: Methanesulfonamide, n-((2s,3s)-1-(2-hydroxy-2-methyl-1-oxopropyl)-2-((2,3',5'-trifluoro(1,1'-biphenyl)-3-yl)methyl)-3-pyrrolidinyl)- · N-((2s,3s)-1-(2-hydroxy-2-methylpropanoyl)-2-((2,3',5'-trifluorobiphenyl-3-yl)methyl)pyrrolidin-3-yl)methanesulfonamide
Code names: TAK-994

Resolves to

Compound

Structure

InChIKeyVOSAWOSMGPKQEQ-OALUTQOASA-NSMILESCC(C)(O)C(=O)N1CC[C@H](NS(C)(=O)=O)[C@@H]1CC1=CC=CC(=C1F)C1=CC(F)=CC(F)=C1

Targets

What you can answer from here — as of August 31, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

5+ReferencesStructured and connected to the statements they support

Which drugs share a target with Firazorexton, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.